{"id":"W4399577197","doi":"10.2139/ssrn.4857103","title":"A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian Partnership Against Cancer; Princess Margaret Cancer Centre; Western University; University of Toronto; Ottawa Hospital; University Health Network; CancerCare Manitoba; University of British Columbia Hospital; Juravinski Hospital; Hôpital Notre-Dame; University of Ottawa; University of British Columbia; Hospital for Sick Children","funders":"","keywords":"Durvalumab; Tremelimumab; Phase (matter); Medicine; Cancer; Oncology; Internal medicine; Chemistry; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001483693,0.001182738,0.002835355,0.00036612,0.0004077684,0.001032919,0.0006828005,0.001056583,0.003431007],"category_scores_gemma":[0.001092424,0.0005875102,0.001803048,0.0003563301,0.001032773,0.0009398718,0.0003928819,0.003128542,0.000839916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009985788,"about_ca_system_score_gemma":0.001589823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001067631,"about_ca_topic_score_gemma":0.002010015,"domain_scores_codex":[0.9994318,0.000293721,0.00002211683,0.00009561541,0.00004025181,0.0001164345],"domain_scores_gemma":[0.9991622,0.0001765005,0.0001135561,0.00009742086,0.00003812201,0.0004122104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8820392,0.02796326,0.004737608,0.0004377502,0.001557699,0.0001932925,0.0001786873,0.001265144,0.01961087,0.000304838,0.002038124,0.05967356],"study_design_scores_gemma":[0.7663812,0.2212263,0.00709427,0.00001948901,0.0006170893,0.0002413661,0.00005814733,0.0006825786,0.001315972,0.0002200711,0.002119099,0.00002445605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941056,0.00191323,0.000404139,0.0004522129,0.0001404453,0.0009957536,0.0007291997,0.00004740814,0.001211955],"genre_scores_gemma":[0.9889903,0.002015005,0.001776786,0.0008909217,0.0002520569,0.001655037,0.002045875,0.00003481277,0.00233921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003431007,"threshold_uncertainty_score":0.01147783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008403775660196117,"score_gpt":0.293999811440135,"score_spread":0.2855960357799389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}